Kineta, Inc rapidly advances leading-edge immunotherapeutic drug candidates through human safety trials, transacts with Pharma, 3 yr. est. to ROI
iCrowdNewswire -
Oct 5, 2016 10:02 AM ET
Kineta, Inc.
Kineta rapidly advances leading-edge immunotherapeutic drug candidates through human safety trials, transacts with Pharma, 3 yr. est. to ROI
Company Summary
Kineta is a biotech company that fills a void in the pharma industry by advancing therapies from discovery to clinical proof of concept. We work with private, government and industry partners to advance our innovative research. Our unique funding model mitigates risk and may provide an attractive and earlier return for investors. Kineta has established and a pipeline of novel life improving therapies that address critical unmet patient needs.
Dr. Iadonato previously co-founded and was CSO of Illumigen Biosciences Inc. where he pioneered the company’s patented drug discovery methodology driven by recruitment and screening of healthy populations. He also led the successful discovery and preclinical development of Illumigen’s anti-HCV drug IB657, which ultimately led to the sale of the company. Earlier he managed the Human Genome Project data collection at the U.W. Genome Center.
Rob Hedequist
President and COO
Unconfirmed
20+ years in the pharmaceutical industry; Corporate development at Kineta; Major Accounts, Managed Care & Sales/ Marketing at Pfizer and Amgen; National Director Schering–Plough